Boehringer Ingelheim, Evotec and bioMérieux forms JV Aurobac to fight antimicrobial resistance
The JV is funded by Boehringer Ingelheim as lead investor with 30 million EUR and by Evotec and bioMérieux with 5 million EUR each.
The JV is funded by Boehringer Ingelheim as lead investor with 30 million EUR and by Evotec and bioMérieux with 5 million EUR each.
The AICVD tool can predict the risk of cardiovascular disease.
Vaccizone’s ASC Technology is an enhanced antigen/bioactive delivery method based on Antigen Presenting Cells
Mittal has previously managed Multiple backed Vikram Hospital as CEO and was associated with Fortis Escorts Heart Institute as zonal director.
Younger Indians have a 10 times higher rate of heart attack
Transcatheter Mitral valve procedure allows intervention on patients who are unsuitable or high risk for open heart surgery
The vaccine is under FDA review
Medicines, including insulin, to be available in 40 lower-income countries
Sanofi will begin to ship their vaccines helping to ensure more people will be immunized
Subscribe To Our Newsletter & Stay Updated